|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latent membrane protein 2A inhibits expression level of Smad2 through regulating miR-155-5p in EBV-associated gastric cancer cell lines.
|
31469179 |
2020 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings reveal a critical role for HMMR in the chemoresistance of GC and suggest that HMMR might be a potential prognostic marker or therapeutic target against the disease.-Zhang, H., Ren, L., Ding, Y., Li, F., Chen, X., Ouyang, Y., Zhang, Y., Zhang, D. Hyaluronan-mediated motility receptor confers resistance to chemotherapy <i>via</i> TGFβ/Smad2-induced epithelial-mesenchymal transition in gastric cancer.
|
30802150 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The cell recovery study found that overexpression of SMAD2 can offset the influence of microRNA-135 mimics on proliferation and metastasis of GC cells, thus affecting the malignant progression of GC.
|
31773690 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of a cDNA array revealed that protocadherin gamma subfamily A, 9 (PCDHGA9) was significantly decreased in SGC-7901 gastric cancer (GC) cells compared with GES-1 normal gastric cells and was strongly associated with the Wnt/β-catenin and transforming growth factor-β (TGF-β)/Smad2/3 signaling pathway.
|
29348665 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
miR-148a downregulates the expression of transforming growth factor-β2 and SMAD2 in gastric cancer.
|
26983401 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to confirm the relationship of miRNA-181b and the TGF-β-Smad2/3/4 pathway with the induction of the epithelial-to-mesenchymal transition (EMT) in gastric cancer.
|
27383203 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In parallel, the downregulated SMAD2/3 phosphorylation in gastric cancer was revived by 5-aza-dC in vivo.
|
26212015 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results document an oncogenic role of PAK4 in repression of Smad2/3 transactivation that involved in tumorigenesis, and suggest PAK4 as a potential therapeutic target for gastric cancer.
|
23934187 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer.
|
22539990 |
2012 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers.
|
11572763 |
2001 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PCR-SSCP analysis of the entire coding region of Smad2 in 35 human sporadic gastric cancers and eight gastric cancer cell lines was performed using 11 sets of intron-based primers.
|
10073143 |
1999 |